ADO-5030 in Bronchoconstriction Challenge, Phase 1b

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
Adovate
Study ID
NCT07281274
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Asthma (Diagnosis)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ADO-5030 — DRUG
    Single oral dose of ADO-5030.

Study Details

This is a Phase 1 study to learn about the safety and pharmacokinetics of the study drug in patients with asthma and whether the study drug has effect during a respiratory challenge.

Key Dates

Start date
Jan 1, 2026
Status verified
Jan 2026
Primary completion
Jun 1, 2026
Completion
Jul 1, 2026

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ADO-5030
    This is a single-arm study. All participants will receive ADO-5030.

Primary Outcome Measure

Change from baseline in PC20 AMP. [ Time Frame: As this is a single dose trial, the timeframe is the duration in which PC20 AMP is reached during the AMP Challenge with ADO-5030 on Day 1. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of VirginiaCharlottesvilleVirginia22904
Deborah Murphy, BSN
[email protected]
434-982-3510
Larry Borish, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlottesville, VA

By research site
University of Virginia· Charlottesville, VA

Related Studies